$KALA
KALA BIO, Inc. Stock $kala

$kala Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000155837023008798 Filed on May 09, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$0.00	$0.00	$1.372M
YoY Change	-100.0%	-100.0%	-57.99%
Cost Of Revenue	$0.00	$0.00	$775.0K
YoY Change	-100.0%	-100.0%	1.97%
Gross Profit	$0.00	$0.00	$597.0K
YoY Change	-100.0%	-100.0%	-76.22%
Gross Profit Margin			43.51%
Selling, General & Admin	$4.962M	$6.030M	$26.98M
YoY Change	-78.11%	-77.65%	-2.59%
% of Gross Profit			4519.6%
Research & Development	$4.278M	$4.036M	$4.466M
YoY Change	-4.36%	-9.63%	42.87%
% of Gross Profit			748.07%
Depreciation & Amortization	$77.00K	$77.00K	$157.0K
YoY Change	-48.32%	-50.96%	-36.69%
% of Gross Profit			26.3%
Operating Expenses	$9.599M	$11.68M	$32.29M
YoY Change	-65.81%	-63.81%	2.24%
Operating Profit	-$9.599M	-$11.68M	-$30.91M
YoY Change	-63.04%	-62.21%	9.18%
Interest Expense	$1.413M	$1.474M	$2.035M
YoY Change	-35.98%	-27.57%	-4.95%
% of Operating Profit
Other Income/Expense, Net	-$814.0K	-$2.772M	-$2.027M
YoY Change	-61.94%	36.75%
Pretax Income	-$10.41M	-$14.46M	-$32.94M
YoY Change	-62.96%	-56.12%	8.32%
Income Tax
% Of Pretax Income
Net Earnings	-$10.41M	-$14.46M	-$32.94M
YoY Change	-62.96%	-56.12%	8.32%
Net Earnings / Revenue			-2400.95%
Basic Earnings Per Share	-$4.36	-$6.99	-$0.45
Diluted Earnings Per Share	-$4.36	-$6.99	-$0.45
COMMON SHARES
Basic Shares Outstanding	2.349M	2.025M	73.64M
Diluted Shares Outstanding	2.388M	2.069M	73.64M

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$59.18M	$63.64M	$70.16M
YoY Change	32.78%	-9.3%	-55.02%
Cash & Equivalents	$49.26M	$63.64M	$65.17M
Short-Term Investments	$9.922M		$4.992M
Other Short-Term Assets	$6.063M	$7.313M	$4.542M
YoY Change	-75.84%	61.01%	74.69%
Inventory			$10.53M
Prepaid Expenses
Receivables	$117.0K	$115.0K	$13.02M
Other Receivables	$177.0K	$280.0K	$0.00
Total Short-Term Assets	$65.54M	$71.34M	$98.26M
YoY Change	-21.53%	-27.39%	-45.13%
LONG-TERM ASSETS
Property, Plant & Equipment	$637.0K	$504.0K	$2.704M
YoY Change	-28.51%	-81.36%	-11.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$328.0K	$372.0K	$9.230M
YoY Change	-36.8%	-95.97%	-51.93%
Total Long-Term Assets	$965.0K	$882.0K	$13.32M
YoY Change	-33.95%	-93.38%	-73.76%
TOTAL ASSETS
Total Short-Term Assets	$65.54M	$71.34M	$98.26M
Total Long-Term Assets	$965.0K	$882.0K	$13.32M
Total Assets	$66.50M	$72.23M	$111.6M
YoY Change	-21.74%	-35.27%	-51.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$760.0K	$997.0K	$6.218M
YoY Change	-92.79%	-83.97%	117.79%
Accrued Expenses	$4.902M	$5.076M	$21.24M
YoY Change	-73.22%	-76.1%	40.2%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00
YoY Change
Total Short-Term Liabilities	$9.851M	$10.27M	$32.76M
YoY Change	-70.05%	-68.66%	63.88%
LONG-TERM LIABILITIES
Long-Term Debt	$33.57M	$33.27M	$79.36M
YoY Change	-57.93%	-58.08%	9.43%
Other Long-Term Liabilities	$5.588M	$5.234M	$4.739M
YoY Change	45.56%	10.45%	-82.77%
Total Long-Term Liabilities	$39.16M	$38.50M	$84.10M
YoY Change	-53.18%	-54.22%	-15.94%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.851M	$10.27M	$32.76M
Total Long-Term Liabilities	$39.16M	$38.50M	$84.10M
Total Liabilities	$49.01M	$48.77M	$116.9M
YoY Change	-57.94%	-58.27%	-2.65%
SHAREHOLDERS EQUITY
Retained Earnings	-$612.1M	-$601.7M	-$575.3M
YoY Change	1.43%	4.58%	33.74%
Common Stock	$3.000K	$2.000K	$73.00K
YoY Change	-95.89%	-97.26%	14.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$17.49M	$23.46M	-$5.284M
YoY Change
Total Liabilities & Shareholders Equity	$66.50M	$72.23M	$111.6M
YoY Change	-21.74%	-35.27%	-51.45%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$10.41M	-$14.46M	-$32.94M
YoY Change	-62.96%	-56.12%	8.32%
Depreciation, Depletion And Amortization	$77.00K	$77.00K	$157.0K
YoY Change	-48.32%	-50.96%	-36.69%
Cash From Operating Activities	-$7.595M	-$9.684M	-$24.09M
YoY Change	-70.12%	-59.8%	-26.2%
INVESTING ACTIVITIES
Capital Expenditures	$214.0K	$108.0K	-$81.00K
YoY Change	-224.42%	-233.33%	-63.18%
Acquisitions
YoY Change
Other Investing Activities	-$9.819M	$0.00	-$4.992M
YoY Change	-427.3%	-100.0%	-110.35%
Cash From Investing Activities	-$10.03M	-$108.0K	-$5.073M
YoY Change	-454.77%	-97.87%	-110.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.073M	2.858M	154.0K
YoY Change	-30830.0%	1755.84%	-99.56%
NET CHANGE
Cash From Operating Activities	-7.595M	-9.684M	-24.09M
Cash From Investing Activities	-10.03M	-108.0K	-5.073M
Cash From Financing Activities	3.073M	2.858M	154.0K
Net Change In Cash	-14.56M	-6.934M	-29.01M
YoY Change	-35.6%	-76.1%	-157.21%
FREE CASH FLOW
Cash From Operating Activities	-$7.595M	-$9.684M	-$24.09M
Capital Expenditures	$214.0K	$108.0K	-$81.00K
Free Cash Flow	-$7.809M	-$9.792M	-$24.01M
YoY Change	-69.07%	-59.21%	-25.95%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2348687
CY2023Q1	kala	Accrued Contract Manufacturing AccruedContractManufacturing	211000
CY2022Q4	kala	Accrued Contract Manufacturing AccruedContractManufacturing	453000
CY2023Q1	kala	Due To Third Party DueToThirdParty	41000
CY2022Q4	kala	Due To Third Party DueToThirdParty	2244000
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	777000
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001479419
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1706971
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2309287
CY2023Q1	kala	Fair Value Assets Level2 To Level1 Transfers Amount1 FairValueAssetsLevel2ToLevel1TransfersAmount1	0
CY2022	kala	Fair Value Assets Level2 To Level1 Transfers Amount1 FairValueAssetsLevel2ToLevel1TransfersAmount1	0
CY2023Q1	kala	Fair Value Liabilities Level1 To Level2 Transfers Amount1 FairValueLiabilitiesLevel1ToLevel2TransfersAmount1	0
CY2022	kala	Fair Value Liabilities Level1 To Level2 Transfers Amount1 FairValueLiabilitiesLevel1ToLevel2TransfersAmount1	0
CY2023Q1	kala	Fair Value Liabilities Level2 To Level1 Transfers Amount1 FairValueLiabilitiesLevel2ToLevel1TransfersAmount1	0
CY2022	kala	Fair Value Liabilities Level2 To Level1 Transfers Amount1 FairValueLiabilitiesLevel2ToLevel1TransfersAmount1	0
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	0
CY2022Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.02
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	50
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-38150
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	KALA PHARMACEUTICALS, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-0604595
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	1167 Massachusetts Avenue
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Arlington
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02476
CY2023Q1	dei	City Area Code CityAreaCode	781
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	996-5252
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2023Q1	dei	Trading Symbol TradingSymbol	KALA
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63636000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	70495000
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2353000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7852000
CY2023Q1	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	5355000
CY2022Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	7595000
CY2023Q1	us-gaap	Assets Current AssetsCurrent	71344000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	85942000
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	504000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	400000
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	16000
CY2023Q1	kala	Restricted Cash And Other Assets Noncurrent RestrictedCashAndOtherAssetsNoncurrent	372000
CY2022Q4	kala	Restricted Cash And Other Assets Noncurrent RestrictedCashAndOtherAssetsNoncurrent	462000
CY2023Q1	us-gaap	Assets Assets	72226000
CY2022Q4	us-gaap	Assets Assets	86820000
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	997000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2832000
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5076000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8910000
CY2023Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	4189000
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	4189000
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	13000
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	5000000
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	4146000
CY2022Q4	kala	Deferred Purchase Consideration Current DeferredPurchaseConsiderationCurrent	595000
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	10265000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25685000
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	33266000
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	37937000
CY2023Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	5234000
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	4224000
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	38500000
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	42161000
CY2023Q1	us-gaap	Liabilities Liabilities	48765000
CY2022Q4	us-gaap	Liabilities Liabilities	67846000
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2309287
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1706971
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	2000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2000
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	625124000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	606182000
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-601665000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-587210000
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	23461000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	18974000
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	72226000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	86820000
CY2022Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1372000
CY2022Q1	kala	Product Revenue Cost ProductRevenueCost	775000
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6030000
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	26982000
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4036000
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4466000
CY2023Q1	kala	Gain Loss On Fair Value Re Measurement Of Deferred Purchase Consideration GainLossOnFairValueReMeasurementOfDeferredPurchaseConsideration	230000
CY2022Q1	kala	Gain Loss On Fair Value Re Measurement Of Deferred Purchase Consideration GainLossOnFairValueReMeasurementOfDeferredPurchaseConsideration	-1051000
CY2023Q1	kala	Gain Loss On Fair Value Re Measurement Of Contingent Consideration GainLossOnFairValueReMeasurementOfContingentConsideration	-1847000
CY2022Q1	kala	Gain Loss On Fair Value Re Measurement Of Contingent Consideration GainLossOnFairValueReMeasurementOfContingentConsideration	988000
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	11683000
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	32286000
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-11683000
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-30914000
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	675000
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	8000
CY2023Q1	us-gaap	Interest Expense InterestExpense	1474000
CY2022Q1	us-gaap	Interest Expense InterestExpense	2035000
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1973000
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2772000
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2027000
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14455000
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-32941000
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.99
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.99
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-22.18
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-22.18
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2069186
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2069186
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1485168
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1485168
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14455000
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-32941000
CY2022Q1	kala	Other Comprehensive Income Available For Sale Securities Adjustments Net Of Tax Portions Attributable To Parent OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentsNetOfTaxPortionsAttributableToParent	-2000
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2000
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14455000
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-32943000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	18974000
CY2023Q1	kala	Payments Of Stock Issuance Costs At Market Offering PaymentsOfStockIssuanceCostsAtMarketOffering	384000
CY2023Q1	kala	Stock Issued During Period Value New Issues At Market StockIssuedDuringPeriodValueNewIssuesAtMarket	14893000
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	6000
CY2023Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	365000
CY2023Q1	kala	Asset Acquisition Contingent Milestone Consideration Equity Interest Issued Or Issuable AssetAcquisitionContingentMilestoneConsiderationEquityInterestIssuedOrIssuable	2354000
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1324000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-14455000
CY2022Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	163000
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2858000
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	154000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6934000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-29008000
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	23461000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	16804000
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3000
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	160000
CY2022Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	7936000
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2756000
CY2022Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-2000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-32941000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-5284000
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-14455000
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-32941000
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	77000
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	157000
CY2023Q1	kala	Non Cash Operating Lease NonCashOperatingLease	10000
CY2022Q1	kala	Non Cash Operating Lease NonCashOperatingLease	181000
CY2023Q1	kala	Gain Loss On Fair Value Re Measurement Of Deferred Purchase Consideration GainLossOnFairValueReMeasurementOfDeferredPurchaseConsideration	230000
CY2022Q1	kala	Gain Loss On Fair Value Re Measurement Of Deferred Purchase Consideration GainLossOnFairValueReMeasurementOfDeferredPurchaseConsideration	-1051000
CY2023Q1	kala	Gain Loss On Fair Value Re Measurement Of Contingent Consideration GainLossOnFairValueReMeasurementOfContingentConsideration	-1847000
CY2022Q1	kala	Gain Loss On Fair Value Re Measurement Of Contingent Consideration GainLossOnFairValueReMeasurementOfContingentConsideration	988000
CY2023Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	329000
CY2022Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	432000
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1324000
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2805000
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	2000
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-80000
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2325000
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-5470000
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1662000
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2189000
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	164000
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1826000
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1222000
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-4489000
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	326000
CY2023Q1	kala	Increase Decrease In Lease And Other Liabilities Noncurrent IncreaseDecreaseInLeaseAndOtherLiabilitiesNoncurrent	-10000
CY2022Q1	kala	Increase Decrease In Lease And Other Liabilities Noncurrent IncreaseDecreaseInLeaseAndOtherLiabilitiesNoncurrent	-155000
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9684000
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24089000
CY2023Q1	kala	Payments To Acquire Property Plant And Equipment And Other Assets PaymentsToAcquirePropertyPlantAndEquipmentAndOtherAssets	108000
CY2022Q1	kala	Payments To Acquire Property Plant And Equipment And Other Assets PaymentsToAcquirePropertyPlantAndEquipmentAndOtherAssets	81000
CY2022Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	4992000
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-108000
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5073000
CY2023Q1	kala	Payment Of Principal On Venture Debt Facility PaymentOfPrincipalOnVentureDebtFacility	10000000
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14893000
CY2023Q1	kala	Payment O Cash Portion Of Dosing Milestone PaymentOCashPortionOfDosingMilestone	2041000
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	9000
CY2023Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	6000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	70745000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	94878000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	63811000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	65870000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	63811000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	65870000
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	175000
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	700000
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63636000
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	65170000
CY2023Q1	kala	Capital Expenditures Incurred But Not Yet Paid Accounts Payable CapitalExpendituresIncurredButNotYetPaidAccountsPayable	67000
CY2022Q1	kala	Capital Expenditures Incurred But Not Yet Paid Accounts Payable CapitalExpendituresIncurredButNotYetPaidAccountsPayable	174000
CY2023Q1	kala	Issuance Of Common Stock To Satisfy Deferred Purchase Consideration In Additional Paid In Capital IssuanceOfCommonStockToSatisfyDeferredPurchaseConsiderationInAdditionalPaidInCapital	365000
CY2023Q1	kala	Asset Acquisition Contingent Milestone Consideration Equity Interest Issued Or Issuable AssetAcquisitionContingentMilestoneConsiderationEquityInterestIssuedOrIssuable	2354000
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	1227000
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	1603000
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	424000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	50
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14455000
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-32941000
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9684000
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24089000
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-601665000
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	31000000.0
CY2022Q3	kala	Disposal Group Including Discontinued Operation Number Of Milestone Payments Per Calendar Year DisposalGroupIncludingDiscontinuedOperationNumberOfMilestonePaymentsPerCalendarYear	1
CY2022Q3	kala	Disposal Group Including Discontinued Operation Number Of Milestone Payments Per Calendar Year DisposalGroupIncludingDiscontinuedOperationNumberOfMilestonePaymentsPerCalendarYear	1
CY2022Q4	kala	Accrued Revenue Reserves AccruedRevenueReserves	807000
CY2023Q1	kala	Development Costs Current DevelopmentCostsCurrent	499000
CY2022Q4	kala	Development Costs Current DevelopmentCostsCurrent	446000
CY2023Q1	kala	Accrued Commercialization Cost AccruedCommercializationCost	262000
CY2022Q4	kala	Due From Alcon DueFromAlcon	5394000
CY2022Q4	us-gaap	Related Party Transaction Due From To Related Party Current RelatedPartyTransactionDueFromToRelatedPartyCurrent	26000
CY2023Q1	us-gaap	Disposal Group Including Discontinued Operation Inventory Current DisposalGroupIncludingDiscontinuedOperationInventoryCurrent	5355000
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Inventory Current DisposalGroupIncludingDiscontinuedOperationInventoryCurrent	7544000
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Property Plant And Equipment Current DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent	51000
CY2023Q1	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	5355000
CY2022Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	7595000
CY2022Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	7935000
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	365000
CY2023Q1	kala	Gain Loss On Fair Value Re Measurement Of Deferred Purchase Consideration GainLossOnFairValueReMeasurementOfDeferredPurchaseConsideration	230000
CY2022Q1	kala	Gain Loss On Fair Value Re Measurement Of Deferred Purchase Consideration GainLossOnFairValueReMeasurementOfDeferredPurchaseConsideration	-1051000
CY2023Q1	kala	Fair Value Assets Level1 To Level2 Transfers Amount1 FairValueAssetsLevel1ToLevel2TransfersAmount1	0
CY2022	kala	Fair Value Assets Level1 To Level2 Transfers Amount1 FairValueAssetsLevel1ToLevel2TransfersAmount1	0
CY2022Q4	kala	Accrued Commercialization Cost AccruedCommercializationCost	271000
CY2023Q1	kala	Due From Alcon DueFromAlcon	683000
CY2022Q4	kala	Due From Alcon DueFromAlcon	5394000
CY2023Q1	us-gaap	Prepaid Insurance PrepaidInsurance	467000
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	698000
CY2023Q1	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	280000
CY2022Q4	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	908000
CY2023Q1	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	115000
CY2022Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	195000
CY2023Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	808000
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	657000
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2353000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7852000
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1440000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	948000
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1089000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3334000
CY2023Q1	kala	Accrued Revenue Reserves AccruedRevenueReserves	757000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	407000
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5076000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8910000
CY2019Q4	us-gaap	Line Of Credit LineOfCredit	450000
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	10000
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	176000
CY2023Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	20000
CY2022Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	40000
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	6000
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	447000
CY2023Q1	us-gaap	Lease Cost LeaseCost	36000
CY2022Q1	us-gaap	Lease Cost LeaseCost	663000
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	10000
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	719000
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y3M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y6M
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.104
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.104
CY2023Q1	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.1644
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	33957000
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	43303000
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	735000
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	806000
CY2023Q1	kala	Debt Instrument Exit Fees Of Total Principal Payments Value DebtInstrumentExitFeesOfTotalPrincipalPaymentsValue	44000
CY2022Q4	kala	Debt Instrument Exit Fees Of Total Principal Payments Value DebtInstrumentExitFeesOfTotalPrincipalPaymentsValue	440000
CY2023Q1	kala	Adjusted Long Term Debt AdjustedLongTermDebt	33266000
CY2022Q4	kala	Adjusted Long Term Debt AdjustedLongTermDebt	42937000
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	5000000
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	33266000
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	37937000
CY2023Q1	kala	Class Of Warrant Or Right Exercisable ClassOfWarrantOrRightExercisable	4303
CY2022	kala	Class Of Warrant Or Right Exercisable ClassOfWarrantOrRightExercisable	4303
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	75000000
CY2023Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	565974
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	75000000
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.219
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0372
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	14.80
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1324000
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2805000
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14455000
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-32941000
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2069186
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2069186
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1485168
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1485168
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.99
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.99
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-22.18
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-22.18
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5654811
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	281600
CY2022Q4	kala	Tax Credit Carryforward Amount Annual Limitation TaxCreditCarryforwardAmountAnnualLimitation	222000
CY2023Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2022Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2023Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0

Files In Submission

Name	View Source	Status
kala-20230331_pre.xml	Edgar Link	unprocessable
0001558370-23-008798-index-headers.html	Edgar Link	pending
0001558370-23-008798-index.html	Edgar Link	pending
0001558370-23-008798.txt	Edgar Link	pending
0001558370-23-008798-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
kala-20230331.xsd	Edgar Link	pending
kala-20230331x10q.htm	Edgar Link	pending
kala-20230331xex31d1.htm	Edgar Link	pending
kala-20230331xex31d2.htm	Edgar Link	pending
kala-20230331xex32d1.htm	Edgar Link	pending
kala-20230331xex32d2.htm	Edgar Link	pending
kala-20230331xex3d2.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
kala-20230331_cal.xml	Edgar Link	unprocessable
kala-20230331_def.xml	Edgar Link	unprocessable
kala-20230331_lab.xml	Edgar Link	unprocessable
kala-20230331x10q_htm.xml	Edgar Link	completed
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KALA
KALA BIO, Inc. Stock $kala

2023 Q2 Form 10-Q Financial Statement

#000155837023008798 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KALA KALA BIO, Inc. Stock $kala

2023 Q2 Form 10-Q Financial Statement

#000155837023008798 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KALA
KALA BIO, Inc. Stock $kala